Song JY, et al. - Via performing this single-center, open-label randomized trial, researchers evaluated the immunogenicity and safety of the tetanus-diphtheria (Td) vaccine and 13-valent pneumococcal conjugate vaccine (PCV13) after concomitant administration in 448 adults aged ≥ 50 years. They randomized the participants 1:1:1 to receive Td plus PCV13 (Group 1), PCV13 alone (Group 2), or Td alone (Group 3). They found that, without significant interference, Td and PCV13 induced sufficient immunity and showed good safety profiles when administered concomitantly.